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Detection of persistent cervical carcinogenic human papillomavirus (HPV) DNA is used as a marker for cervical
cancer risk in clinical trials. The authors performed a systematic review and meta-analysis of the association between
persistent HPV DNA and high-grade cervical intraepithelial neoplasia (CIN2-3), high-grade squamous intraepithelial
lesions (HSIL), and invasive cervical cancer (together designated CIN2-3/HSILþ) to evaluate the robustness of HPV
persistence for clinical use. MEDLINE and Current Contents were searched through January 30, 2006. Relative risks
(RRs) were stratified by HPV comparison group. Of 2,035 abstracts, 41 studies were eligible for inclusion in the meta-
analysis. Over 22,500 women were included in calculation of RRs for persistent HPV DNA detection and cervical
neoplasia. RRs ranged from 1.3 (95% confidence interval: 1.1, 1.5) to 813.0 (95% confidence interval: 168.2,
3,229.2) for CIN2-3/HSILþ versus <CIN2-3/HSILþ; 92% of RRs were above 3.0. Longer durations of infection (>12
months), wider testing intervals, CIN2-3/HSILþ, and use of an HPV-negative reference group were consistently asso-
ciated with higher RRs. Thus, HPV persistence was consistently and strongly associated with CIN2-3/HSILþ, despite
wide variation in definitions and study methods. The magnitude of association varied by duration of persistence and
testing interval. Precise definition and standardization of HPV testing, sampling procedure, and test interval are needed
for reliable clinical testing. These findings validate HPV persistence as a clinical marker and endpoint.
human papillomavirus 16; human papillomavirus 18; longitudinal studies; papillomavirus infections; uterine
cervical neoplasms
Abbreviations: ASCUS, atypical squamous cells of undetermined significance; CI, confidence interval; CIN, cervical
intraepithelial neoplasia; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesions; LSIL, low-grade
squamous intraepithelial lesions; PCR, polymerase chain reaction; SIL, squamous intraepithelial lesions.
Editor’s note: An invited commentary on this article appears
on page 134, and the authors’ response appears on page 145.
Carcinogenic human papillomavirus (HPV) infection is
necessary for the development of cervical cancer (1–3), the
second most common cancer in women worldwide (4).
Although carcinogenic HPV types are found in virtually
all invasive cervical cancer, with types 16 and 18 being
found in approximately 70 percent of cases (5–7), HPV
infection is common among young women (8, 9). Most
infections become undetectable within 1–2 years (10, 11).
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Thus, infection alone is not sufficient to cause cervical
cancer.
Persistent HPV infections are considered to drive progres-
sion of cervical neoplasia to invasive cervical cancer (12).
Laboratory evidence shows that continued HPV oncogene
expression is critical for the maintenance and progression of
cervical neoplasia (13). Several studies have suggested that
detection of the same carcinogenic HPV type over time is
particularly important for cervical carcinogenesis (14–16).
Thus, type-specific persistence of carcinogenic HPV DNA
has been used as a surrogate endpoint for risk of cervical
cancer in vaccine trials (17, 18) and as a diagnostic marker
for high-grade cervical intraepithelial neoplasia (CIN2-3) in
cervical cancer screening studies (19, 20).
While HPV persistence is commonly defined as having
two or more HPV DNA-positive tests (21, 22), other inves-
tigators have evaluated HPV persistence using time to clear-
ance (i.e., duration) (23–25) or proportion of HPV-positive
visits (26, 27). Definitions of HPV persistence are further
complicated by differences in HPV laboratory detection
methods, testing intervals, and HPV categorization and sta-
tus for analysis (e.g., type-specific vs. non-type-specific
HPV persistence; restriction to carcinogenic types, individ-
ual types, or overall HPV positivity; baseline HPV status;
and clearance requirements). A clearer understanding of
how investigators have estimated the association between
HPV persistence and high-grade precancer and cancer
would provide a basis for interpreting available data and
reaching consensus on a standardized definition of HPV
persistence for future studies and clinical use. Thus, we
performed a systematic review to identify variations in the
definitions of HPV persistence within the published litera-
ture and to determine the strength of the association between
HPV persistence and cervical neoplasia and the influence of
study characteristics on this association.
MATERIALS AND METHODS
Data abstraction
We identified relevant studies by searching MEDLINE
(via PubMed), Current Contents, and reference lists from
eligible articles through January 30, 2006. No language
or publication starting-date limitations were imposed. Broad
search-term categories included HPV, persistence (e.g., per-
sistent, clearance, duration), and cervical disease (e.g., cervi-
cal dysplasia, squamous intraepithelial lesions (SIL), cervical
intraepithelial neoplasia (CIN)) (specific search terms avail-
able upon request). Peer-reviewed publications that used
HPV DNA detection in humans were eligible if they either
reported or had calculable relative risks (risk ratios, rate
ratios, odds ratios, or hazard ratios, hereafter termed ‘‘rela-
tive risks’’) and corresponding 95 percent confidence inter-
vals for the association between HPV persistence and
cervical neoplasia. Posttreatment studies and studies that
provided only baseline data on cervical neoplasia were ex-
cluded. Cervical outcomes included invasive cervical can-
cer, CIN2-3, and high-grade SIL (HSIL); low-grade CIN1 or
low-grade SIL (LSIL); atypical squamous cells of undeter-
mined significance (ASCUS); or any combination of the
above (e.g., any SIL). Cervical cancer, CIN2-3, and HSIL
were combined for formal analyses and termed ‘‘CIN2-3/
HSILþ,’’ although histologically based diagnoses were ex-
amined separately where possible and assessed in study
characteristic analyses. Similarly, low-grade CIN and LSIL
were combined and termed ‘‘CIN1/LSIL.’’ For simplicity,
the term ‘‘CIN2’’ is used to describe both cytologically di-
agnosed moderate dysplasia and histologically diagnosed
CIN2, and ‘‘CIN3’’ describes both cytologically diagnosed
severe dysplasia and histologically diagnosed CIN3.
We abstracted relative risks and 95 percent confidence
intervals if they were reported or calculated them ourselves
for the risk of cervical neoplasia among women with per-
sistent HPV infections as compared with 1) women who
were consistently negative for the HPV types used to define
persistence (hereafter termed the ‘‘HPV-negative referent
group’’), 2) women who had HPV infections that became un-
detectable (the ‘‘transient HPV referent group’’), or 3) a mix of
women who were negative or had transient and/or incident
HPV infection (the ‘‘mixed HPV referent group’’). For
author-calculated relative risks, 0.5 was added to each of
the four interior cells if one of the cells contained zero.
For studies with adjusted relative risks, the most adjusted
relative risk (i.e., controlled for the largest number of poten-
tial confounders) was used for analyses.
Abstracted data included HPV type or group (individual
types (e.g., HPV16), overall HPV positivity (any type),
combined carcinogenic types), type-specificity (same HPV
type or different types across time), HPV detection method,
HPV testing interval, baseline HPV status, cervical status
(e.g., baseline status, cervical outcome diagnostic method,
and severity of lesion), demographic data (e.g., age, human
immunodeficiency virus serostatus), and other study char-
acteristics (e.g., sample size, study design, number of visits).
Two independent reviewers abstracted and confirmed data
from each article to ensure accuracy. Study authors were
contacted for clarification of HPV persistence and cervical
outcome definitions as needed.
Selection of relative risks
Several articles that were eligible for inclusion were
based on the same study population (11, 28–41). In these
cases, the article with the largest number of women was
used, unless multiple articles could contribute to separate
analyses (11, 29–32, 37–39).
In formal analyses, we focused on associations between
HPV persistence and CIN2-3/HSILþ. Relative risks for
CIN1/LSIL were included only for comparisons with
CIN2-3/HSILþ, since CIN1/LSIL reflects active HPV rep-
lication and is generally managed clinically by follow-up
rather than immediate treatment (42–44). Relative risks for
the outcome ‘‘any lesion,’’ which combined lesions with low
and high risk for progression to invasion, were not included.
Some studies provided multiple relative risks with differ-
ing definitions of HPV persistence or cervical outcome. In
these cases, we applied the following decision rules to select
one relative risk per study for meta-analyses, thereby main-
taining the independence of observations: 1) relative risks
for HPV16 persistence were chosen first, followed by
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HPV18, HPV16/18, other individual carcinogenic types,
combined carcinogenic types, and overall HPV (any type);
2) type-specific relative risks were chosen over non-type-
specific relative risks; 3) relative risks for CIN2-3/HSILþ
were chosen first, followed by relative risks for cancer only,
CIN3 only, and CIN2 only; 4) relative risks based on histo-
logic diagnosis only were chosen first; and 5) HPV persis-
tence definitions involving more HPV-positive visits were
chosen over definitions involving fewer HPV-positive visits
(e.g., three HPV-positive visits vs. two).
Statistical analyses
Cochran’s Q two-sided homogeneity p value (45) was
used to assess overall heterogeneity in relative risks. Funnel
plots were created by plotting the relative risks by their
precision (46). These plots were statistically evaluated for
asymmetry, using 1) Begg rank correlation (47), 2) Egger
regression (48), and 3) the Duval and Tweedie ‘‘trim and
fill’’ method (49), which imputes results that are hypothet-
ically missing due to publication bias. Asymmetry can re-
flect publication bias, random error, or study characteristics
associated with sample size (46). Since nearly 70 percent of
relative risks in this review were calculated by us from data
provided in the articles, funnel plot asymmetry analyses
were also stratified by study purpose (i.e., studies that spe-
cifically assessed the relation between HPV persistence and
cervical neoplasia vs. those that did not).
Analyses of study characteristics. To assess variation in
the strength of the association between HPV persistence and
CIN2-3/HSILþ by differences across studies, we evaluated
key study characteristics using stratified random-effects
meta-analysis and restricted maximum likelihood meta-
regression. Stratified meta-analysis allows descriptive com-
parison of summary relative risks across individual catego-
ries of a specified study characteristic (e.g., by providing
separate summary relative risks for polymerase chain reac-
tion (PCR)-based and non-PCR-based HPV persistence).
Restricted maximum likelihood meta-regression formally
compares differences in relative risks across study charac-
teristic categories (e.g., ratio of PCR-based to non-PCR-
based relative risks) and estimates among-study variance
(50). Given inherent differences in comparing persistent in-
fections with HPV-negative, transient, and mixed infections,
all analyses were stratified by HPV referent group. We as-
sessed the consistency of study characteristic results across
all three referent groups to distinguish true study character-
istic effects from random variation.
Analyses of study characteristics focused on relative risks
with CIN2-3/HSILþ as the outcome, given its clinical rel-
evance, and on characteristics related to HPV persistence
and cervical status (e.g., HPV testing interval and method of
outcome diagnosis). For these analyses, we allowed studies
to contribute relative risks to more than one category in
order to reduce any potential influence of the decision rules
on the distribution of study characteristics. Where studies
contributed to more than one category, meta-regression con-
fidence intervals may be influenced by the incomplete in-
dependence of observations. We also analyzed disease
severity to formally compare relative risks that used CIN2-
3/HSILþ as the outcome with those that used CIN1/LSIL.
Sensitivity analysis. We performed sensitivity analyses
using reasonable alternative decision rules to assess the in-
fluence of the above decision rules on the strength and sta-
bility of meta-analytic and study characteristic results. The
first sensitivity analysis reversed the order of decision rule 1
so that relative risks for overall HPV persistence were cho-
sen first and HPV16 last. The second sensitivity analysis
changed decision rule 3 from the choice of CIN2-3/HSILþ
(initially selected for increased estimate stability and be-
cause treatment guidelines are based on CIN2 and CIN3
combined) (42, 44) to the choice of cancer only first, fol-
lowed by CIN3 only, CIN2 only, and then CIN2-3/HSILþ.
The sensitivity of the results to these decision rule changes
was evaluated by descriptively comparing the homogeneity
p value, funnel plots, and Begg and Egger two-sided p val-
ues and the magnitude and precision of random-effects
summary relative risks. In addition, results of study charac-
teristic analyses in which studies contributed relative risks
to more than one category were compared with those with
only one relative risk per study.
RESULTS
Descriptive results
Eligible studies. Over 22,500 women were included in
the calculation of relative risks from 41 eligible studies of 37
unique populations identified from 2,035 abstracts. Three
studies were clinical trials and 38 were cohort-based, in-
cluding six nested case-control studies (16, 29–31, 37, 51)
and one follow-up of a case-control study (52) (table 1).
Most studies required normal cervical diagnosis at study
entry, although some included both women with normal
diagnoses and a proportion with ASCUS or cervical neo-
plasia at baseline. Study populations were predominately
population- or cervical screening-based and European or
North American.
Definitions of HPV persistence. Definitions of HPV per-
sistence varied considerably across studies (table 1). Most
studies (78 percent) defined persistence as HPV positivity at
two or more time points, whereas others used three or more
HPV-positive visits, the proportion of HPV-positive visits,
HPV positivity throughout study follow-up, or time to clear-
ance. Persistence was defined as HPV positivity at only two
time points in approximately 50 percent of the studies (n ¼
19) (14, 16, 20, 32, 37–39, 51–62). Consecutive positivity
was generally required, although intervening HPV-negative
visits were allowed in some studies (11, 25, 27, 62–66). The
minimum duration of HPV persistence (i.e., the shortest
period of HPV detection necessary for a woman to be clas-
sified as having persistent infection) was less than 6 months
for 30 percent of studies, 6–12 months for 45 percent, and
more than 12 months for 25 percent. The median time be-
tween HPV tests was 6 months (range, 2–72 months). Only
seven studies clearly identified two or more HPV-positive
visits prior to cervical outcome diagnosis (11, 29–31, 58, 62,
67). Most studies (80 percent) used PCR for HPV DNA
detection. The hybrid capture assay was the most common
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TABLE 1. Distribution of relative risks for the association between human papillomavirus persistence and








Cohort study 38 92.7 10, 11, 14, 16, 20, 25, 27, 29–32, 37–39,
51–65, 67–71, 75, 102–104
Clinical trial 3 7.3 17, 66, 105
Baseline cervical status*
Normal 24 60.0 10, 16, 17, 29–32, 37–39, 51, 56, 57, 60, 61,
64–68, 71, 75, 102, 104
Normal/ASCUSy 6 15.0 11, 54, 58, 59, 62, 70
Normal/lesions 10 25.0 14, 20, 25, 27, 52, 53, 63, 69, 103, 105
Population
Population-based 5 12.2 14, 17, 37, 60, 62
Screening-based 15 36.6 16, 29–32, 38, 39, 51, 54, 56–59, 61, 75
GYNy/STIy/hospital-based 9 22.0 20, 27, 52, 53, 55, 67, 102–104
Other 12 29.3 10, 11, 25, 63–71
Continent
Europe 20 48.8 16, 20, 27, 29–32, 37–39, 53–56, 58–60,
69, 75, 102
North America 16 39.0 10, 11, 25, 51, 52, 57, 61, 63–68, 70, 71, 105
Other 5 12.2 14, 17, 62, 103, 104
Definition of HPVy persistencez
2 HPV-positive visits 32 78.0 10, 11, 14, 16, 17, 20, 30–32, 37–39, 51–62,
64–67, 70, 103–105
3 HPV-positive visits 8 19.5 11, 29, 62, 67–69, 71, 75
Proportion of HPV-positive visits 2 4.9 27, 63
HPV-positive throughout follow-up 1 2.4 102
Time to HPV clearance 1 2.4 25
Minimum duration of HPV infection
(months)§
<6 12 30.0 11, 20, 25, 32, 52, 55, 62, 64, 67, 103–105
6–12 18 45.0 10, 11, 17, 37, 51, 53, 54, 57, 58, 61–63,
65, 66, 68, 70, 71, 75
>12 10 25.0 14, 16, 27, 29, 38, 39, 56, 59, 69, 102
Baseline HPV status{
Positive 10 24.4 11, 32, 38, 39, 52, 58, 60, 61, 75, 104
Negative 2 4.9 17, 105
Both 29 70.7 10, 14, 16, 20, 25, 29–31, 37, 51, 53–57, 59,
61–71, 102, 103
HPV DNA detection method
Polymerase chain reaction 33 80.5 10, 14, 16, 17, 25, 27, 29–31, 37–39, 51–53,
56–60, 62–66, 68–71, 75, 103–105
Hybrid capture 5 12.2 20, 32, 54, 55, 102
Other 3 7.3 11, 61, 67
* One study did not evaluate cervical status at baseline (55).
y ASCUS, atypical squamous cells of undetermined significance; GYN, gynecology; STI, sexually transmitted
infection; HPV, human papillomavirus.
zNumbers of studies add up to more than 41 and percentages to more than 100 because some studies (11, 62, 67)
used more than one definition of HPV persistence.
§ Three studies did not provide enough data to establish minimum duration of HPV infection (30, 31, 60), and two
studies contributed to more than one category (11, 62).
{ One study did not provide data on baseline HPV DNA status (27) and one contributed to more than one
category (61).
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non-PCR assay. At baseline, most studies included both
HPV-positive and HPV-negative women, although two stud-
ies required HPV negativity (5 percent) and nine required
HPV positivity (22 percent).
Cervical neoplasia. A total of 231 relative risks were avail-
able for calculation of the association between HPV persis-
tence and cervical neoplasia (see the Web Appendix, which is
posted on the Journal’s website (http://aje.oxfordjournals.
org/)). Seventy-seven relative risks (33 percent) used an
HPV-negative referent group, 89 (39 percent) a transient
HPV referent group, and 65 (28 percent) a mixed HPV ref-
erent group. Forty-one percent used type-specific HPV per-
sistence definitions, and 59 percent used non-type-specific
definitions. Twenty relative risks were for HPV16 persis-
tence, two were for HPV18, and 11 were for either HPV16
or HPV18. Only 32 percent of 25 studies with data on CIN2-
3/HSILþ provided information on multiple HPV types, and
that information was generally limited to the proportion of
women who had multiple types.
CIN2-3/HSILþ comprised 44 percent of outcomes;
CIN1/LSIL, 14 percent; ASCUS, 7 percent; any lesion
(CIN/SIL), 25 percent; and any ASCUS or lesion, 10 per-
cent. Outcome diagnosis was based on histology (26 per-
cent), cytology and histology (17 percent), cytology only
(55 percent), or colposcopic impression (1 percent) (see
Web Appendix).
Six studies provided 17 relative risks from populations
including human immunodeficiency virus-positive women
(25, 63, 68–71) (see Web Appendix). Relative risks from
these studies ranged from 0.98 (95 percent confidence in-
terval (CI): 0.7, 1.4) for LSIL to 18.1 (95 percent CI: 2.6,
125.0) for HSIL (69). Given that human immunodeficiency
virus-positive and -negative women have different risks of
incident HPV infection and progression to cervical neopla-
sia due to immunosuppression (72–74), these relative risks
were not included in further analyses.
Analytic results
Association between HPV persistence and CIN2-3/
HSILþ. There was notable variation in the magnitude and
precision of relative risks for HPV persistence and CIN2-3/
HSILþ, which ranged from 1.3 (95 percent CI: 1.1, 1.5) (75)
to 813.0 (95 percent CI: 168.2, 3,229.2) (37) (see Web
Appendix). There were 13 relative risks for HPV16 persis-
tence (ranging from 2.0 (95 percent CI: 0.14, 28.0) for
cytologically diagnosed CIN2 (38) to 94.6 (95 percent CI:
53.4, 167.7) for histologically diagnosed CIN3þ (14)), two
relative risks for HPV18 persistence (ranging from 4.5 (95
percent CI: 0.24, 85.1) for cytologically diagnosed CIN2
(38) to 90.6 (95 percent CI: 36.1, 227.4) for histologically
diagnosed CIN3þ (14)), and three relative risks for HPV16
and/or HPV18 persistence (ranging from 7.5 (95 percent CI:
0.39, 142.9) for cytologically diagnosed CIN2 (38) to 12.3
(95 percent CI: 2.6, 57.5) for HSIL (62)).
Figure 1 presents a forest plot of 33 relative risks for HPV
persistence and CIN2-3/HSILþ selected through the above-
described decision rules for each HPV referent group. All
associations were positive, although heterogeneous, and al-
most all lower 95 percent limits were above 1. Descriptively,
associations appeared stronger when women with persistent
HPV infections were compared with uninfected women than
when they were compared with women with transient in-
fections. Median relative risks were 33.3 for studies with an
HPV-negative referent group (homogeneity p < 0.0005),
29.8 for a mixed HPV referent group (homogeneity p <
0.0005), and 14.7 for a transient HPV referent group (ho-
mogeneity p ¼ 0.1). Five relative risks required women to
have persistent HPV infection (two or more HPV-positive
visits) prior to diagnosis of CIN2-3/HSILþ (11, 29–31, 67);
the magnitudes of these relative risks seemed qualitatively
similar to those of the other 28 relative risks.
Only five studies provided relative risks for type-specific
HPV persistence and histologically diagnosed CIN2-3 (14,
29, 52, 60, 75) (table 2 and shaded rows in the Web Appen-
dix). These relative risks appeared to be descriptively sim-
ilar in magnitude to the other relative risks in figure 1. Six
studies from five unique study populations in figure 1 pro-
vided relative risks based on cytologic, colposcopic, or cy-
tologic/histologic diagnosis of CIN2-3/HSILþ (30, 31, 37,
39, 56, 62) (table 2). The relative risks generally appeared to
be similar to those based solely on histology. Formal anal-
yses of differences by histology and type-specificity were
conducted through meta-regression, as presented in table 3.
(An enhanced version of table 3 including reference
numbers is posted on the Journal’s website (http://aje.
oxfordjournals.org/) as online table 3.)
Funnel plot asymmetry. Assessment of funnel plot asym-
metry for HPV persistence and CIN2-3/HSILþ relative
risks suggested that there was no notable evidence of asym-
metry within the HPV-negative (Begg p ¼ 0.5, Egger p ¼
0.1) and mixed HPV (Begg p ¼ 0.9, Egger p ¼ 1.0) referent
categories. The Duval and Tweedie ‘‘trim and fill’’ imputa-
tion method (49) had no effect on these results. Relative
risks with a transient HPV referent showed some evidence
of funnel plot asymmetry (Begg p ¼ 0.4, Egger p ¼ 0.002).
The Duval and Tweedie method imputed data for seven
hypothetically missing studies, which reduced the random-
effects summary relative risk from 14.4 to 7.2. After strat-
ification of the results by study purpose, all p values were
greater than 0.1, which suggests, reduced power notwith-
standing, that overall asymmetry is more likely due to study
characteristics (described below) than to publication bias.
Evaluation of study characteristics. Given the small num-
ber of studies in each category of a given study character-
istic (table 3), study characteristics were evaluated
according to consistency in the direction of the ratios of
relative risks across HPV referent groups. Associations be-
tween HPV persistence and CIN2-3/HSILþ appeared stron-
ger when persistence was defined as HPV infection lasting
for more than 12 months versus 12 months or less (the ratio
of relative risks was 3.3 (95 percent CI: 0.13, 84.0) for the
HPV-negative referent group, 4.3 (95 percent CI: 1.0, 18.0)
for the transient HPV referent group, and 2.4 (95 percent CI:
0.63, 8.9) for the mixed HPV referent group), although the
ratios of relative risks were imprecise, as indicated by the
wide confidence intervals (table 3). This pattern was sup-
ported by trends in the ratios for HPV testing intervals;
relative risks were highest for testing intervals of >12
months, followed by >6–12 months and then 6 months.
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However, even the shortest HPV duration and testing intervals
produced summary relative risks over 9.0. Other study char-
acteristics assessed (e.g., type-specificity) produced inconsis-
tent results across the three HPV referent groups (table 3).
Additional characteristics (e.g., study location) were also
inconsistent or were not reported in sufficient detail (e.g., smok-
ing, sexual practices, oral contraceptive use) for us to assess
in this review (data not shown). Baseline HPV status, minimum
number of visits for HPV persistence, intervening HPV-negative
visits, HPV persistence defined prior to the outcome, hand
calculation of relative risks, censoring at treatment, health-
care provider HPV collection versus self-collection, anatom-
ical sampling location, and time between visits could not be
evaluated, since fewer than two relative risks were available
for each stratum of the study characteristic.
In general, HPV persistence was strongly and positively
associated with all grades of cervical neoplasia, although
associations appeared stronger for CIN2-3/HSILþ than for
CIN1/LSIL, regardless of HPV referent group (figures 2, 3,
and 4).
Sensitivity analyses. We conducted sensitivity analyses
to evaluate the impact of the hierarchical decision rules used
to select relative risks for analyses when multiple relative
risks were available for a given study. Meta-analytic results
seemed robust to changes in the order of the decision rules
regarding HPV group or cervical outcome category within
each HPV referent category. For example, changing the
order of the HPV group favored in the decision rules did
not change the homogeneity, Begg, or Egger p values (p <
0.0005, p ¼ 0.5, and p ¼ 0.1, respectively) for relative risks
FIGURE 1. Relative risks (RRs) and 95% confidence intervals (CIs) for associations between human papillomavirus (HPV) persistence and high-
grade cervical intraepithelial neoplasia, high-grade squamous intraepithelial lesions, and invasive cervical cancer, by HPV referent group, in the
published literature. Results are organized first by outcome diagnosis, then type-specificity, and then baseline cervical status within each HPV
referent group.
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in the HPV-negative referent group, and use of a summary
relative risk was not indicated in either case (data available
upon request). Study characteristic analyses also appeared
robust to changes in the order of the decision rules and
produced similar results when analyses were restricted to
one relative risk per study.
TABLE 2. Selected characteristics of studies contributing to a meta-analysis of human papillomavirus
persistence and high-grade cervical intraepithelial neoplasia, high-grade squamous intraepithelial lesions,
and invasive cervical cancer







Koutsky et al. (67) Histology Non-type-specific overall HPV 26.0 6.5, 112.0
Wallin et al. (16) Histology Non-type-specific overall HPV 213.4 18.1, 1,600.0
Cuzick et al. (54) Histology Non-type-specific carcinogenic HPV 14.0 0.83, 237.5
Dalstein et al. (102) Histology Non-type-specific carcinogenic HPV 239.9 14.8, 3,893.5
Bais et al. (53) Histology Carcinogenic HPVz 27.5 1.6, 474.6
Kjaer et al. (37) Not histology only Type-specific overall HPV 813.0 168.2, 3,229.2
Moberg et al. (30) Not histology only Type-specific HPV16 33.3 17.7, 62.7
Schlecht et al. (62) Not histology only Type-specific HPV16/HPV18 12.3 2.6, 57.5
Liaw et al. (51) Not histology only Non-type-specific overall HPV 497.1 29.8, 8,290.2
Mixed HPV referent group
Schiffman et al. (14) Histology Type-specific HPV16 94.6 53.4, 167.7
Wallin et al. (16) Histology Non-type-specific overall HPV 36.1 4.8, 271.6
Cuzick et al. (54) Histology Non-type-specific carcinogenic HPV 29.8 1.8, 507.3
Dalstein et al. (102) Histology Non-type-specific carcinogenic HPV 260.6 16.1, 4,229.3
Dannecker et al. (55) Histology Non-type-specific carcinogenic HPV 5.7 2.9, 11.3
Paraskevaidis et al. (27) Histology Carcinogenic HPVz 21.3 10.3, 44.3
Bais et al. (53) Histology Carcinogenic HPVz 36.9 2.1, 638.2
Elfgren et al. (56) Not histology only Type-specific HPV16 27.3 1.4, 452.0
Ylitalo et al. (31) Not histology only Type-specific HPV16 25.9 9.3, 72.1
Liaw et al. (51) Not histology only Non-type-specific overall HPV 26.8 12.4, 57.6
Kjaer et al. (37) Not histology only Non-type-specific overall HPV 46.6 25.8, 83.8
Transient HPV referent
group
ter Harmsel et al. (75) Histology Type-specific HPV16 9.4 1.3, 68.4
Beskow et al. (29) Histology Type-specific HPV16 79.0 10.4, 597.3
Peto et al. (60) Histology Type-specific carcinogenic HPV 37.1 2.2, 620.5
Harris et al. (52) Histology Type-specific carcinogenic HPV 5.4 3.2, 9.2
Wallin et al. (16) Histology Non-type-specific overall HPV 13.5 0.98, 185.5
Bory et al. (32) Histology Non-type-specific carcinogenic HPV 119.1 7.4, 1,926.2
Cuzick et al. (54) Histology Carcinogenic HPVz 14.7 0.87, 249.6
Dalstein et al. (102) Histology Non-type-specific carcinogenic HPV 88.2 5.5, 1,427.9
Bais et al. (53) Histology Carcinogenic HPVz 9.4 0.56, 157.2
Cuschieri et al. (39) Not histology only Type-specific carcinogenic HPV 22.9 1.3, 408.1
Liaw et al. (51) Not histology only Non-type-specific overall HPV 8.6 2.5, 30.0
Kjaer et al. (37) Not histology only Non-type-specific overall HPV 18.2 6.1, 54.3
Moscicki et al. (11) Not histology only Non-type-specific carcinogenic HPV 14.1 2.3, 84.5
* HPV, human papillomavirus.
yRelative risks are organized first by outcome diagnosis, then type-specificity, and then baseline cervical status
within each HPV referent group.
zHPV type-specificity was not specified.
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TABLE 3. Effect of study characteristics on the association between human papillomavirus (HPV) persistence and high-grade cervical intraepithelial neoplasia, high-grade
squamous intraepithelial lesions, and invasive cervical cancer, by HPV referent group,* in a meta-analysis of the published literature
Study characteristic























95% CI RR 95% CI
Ratio of
RRs




Minimum duration of HPV
persistence (months)
12 6 (<0.001) 63.9 7.9, 516.7 1.0 5 (<0.001) 21.5 7.4, 62.1 1.0. 8 (0.4) 9.5 5.5, 16.4. 1.0
>12 2 (0.96) 223.0 39.0, 1,273.3 3.3 0.13, 84.0 5 (0.02) 50.0 18.7, 134.1 2.4 0.63, 8.9 4 (0.7) 42.9 12.3, 149.6 4.3 1.0, 18.0
HPV testing interval
(months)
6 3 (0.2) 29.0 7.6, 110.7 1.0 3 (0.003) 18.7 4.5, 77.6 1.0 4 (0.2) 9.4 3.6, 24.3 1.0
>6–12 3 (0.2) 57.7 6.7, 495.9 2.3 0.34, 15.3 3 (0.98) 27.6 13.5, 56.4 2.0 0.53, 7.9 4 (0.4) 13.0 4.8, 35.0 2.0 0.66, 6.0
>12 2 (0.4) 667.9 264.1, 1,689.1 31.1 11.0, 87.6 4 (0.3) 63.2 39.1, 102.0 4.2 1.4, 12.8 3 (0.96) 17.9 6.9, 46.6. 2.8 0.95, 8.1
HPV group
Overall HPV 5 (<0.001) 104.2 11.9, 912.1 1.0 3 (0.5) 37.8 24.0, 59.6 1.0 4 (0.9) 13.3 6.2, 28.5 1.0
Carcinogenic types 5 (0.4) 30.6 17.7, 59.2 0.57 0.05, 6.6z 5 (0.01) 20.3 6.5, 62.9. 0.42 0.11, 1.8 8 (0.1) 15.4 6.2, 38.2 1.0 0.28, 3.9z
HPV16/HPV18 2 (0.2) 26.3 11.4, 60.8 0.35 0.02, 7.4z 3 (0.08) 50.5 17.6, 144.8. 1.4 0.37, 5.6 3 (0.1) 15.5 3.0, 80.6 1.2 0.22, 6.5z
Type-specific persistence
No 7 (0.02) 102.4 27.0, 388.1 1.0 6 (<0.001) 27.3 9.9, 75.1 1.0 8 (0.7) 16.0 18.4, 30.4 1.0
Yes 3 (<0.001) 74.0 5.2, 1,061.1 0.77 0.07, 8.9z 3 (0.08) 50.5 17.6, 144.8 1.9 0.42, 8.3 5 (0.07) 14.9 4.6, 48.9 0.66 0.21, 2.0z
HPV detection method
Non-PCRy 3 (0.3) 36.5 9.4, 141.3 1.0 3 (0.02) 26.5 2.4, 286.1 1.0 4 (0.5) 29.9 9.0, 99.4 1.0
PCR 6 (<0.001) 99.4 15.2, 652.1 2.4 0.19, 31.5 8 (0.06) 38.5 23.9, 62.2 3.2 0.91, 10.9 9 (0.2) 11.4 6.2, 20.9 0.37 0.09, 1.6
Outcome diagnosis
Not histology only 4 (<0.001) 108.2 10.6, 1,107.5 1.0 4 (0.6) 35.3 23.2, 53.6 1.0 5 (0.6) 15.7 7.8, 31.8 1.0
Histology only§ 5 (0.5) 49.4 17.0, 143.6 0.51 0.05, 5.4 7 (<0.001) 32.8 10.2, 105.3 0.94 0.25, 3.5 9 (0.06) 18.7 7.2, 48.5 0.95 0.27, 3.4z
Baseline cervical status
Normal/lesions 2 (0.3) 82.7 9.9, 693.0 1.0 4 (0.01) 55.3 17.5, 174.3 1.0 3 (0.1) 10.8 2.3, 51.0 1.0
Normal/ASCUSy 2 (0.9) 12.7 3.3, 49.3 0.16 0.004, 6.2 1 (NAy) NA NA 2 (0.98) 14.3 3.1, 65.4 2.4 0.48, 11.8
Normal 5 (<0.001) 141.0 19.8, 1,004.7 1.7 0.08, 36.5 5 (0.8) 35.4 23.5, 53.3 0.64 0.24, 1.7 8 (0.6) 18.4 9.8, 37.7 3.1 1.4, 6.9
Mean or median age
(years) of study
population
35 4 (<0.001) 57.7 5.9, 563.9 1.0 4 (0.4) 32.5 21.5, 49.1 1.0 4 (0.2) 9.6 4.4, 21.7 1.0
>35 4 (0.4) 76.6 19.1, 308.2 1.1 0.08, 16.0 5 (0.03) 26.4 6.0, 116.8 0.58 0.16, 2.1 6 (0.6) 20.9 7.3, 59.5 2.3 0.61, 8.6
* HPV-negative, transient HPV, or mixed.
yRR, relative risk; CI, confidence interval; PCR, polymerase chain reaction; ASCUS, atypical squamous cells of undetermined significance; NA, not applicable.
z At least one study contributed effect estimates to more than one category. Thus, observations are not independent and 95% confidence intervals may be inaccurate.







































To our knowledge, this review of 41 studies with over
22,500 women is the first systematic evaluation of the asso-
ciation between HPV persistence and cervical neoplasia.
Concerted efforts were made to include all published study
results, including translation of foreign-language papers and
a full article review for every abstract suggesting data on
HPV persistence and cervical neoplasia. All abstracted data
were reviewed twice by independent readers to ensure data
accuracy. Relative risks were selected through decision rules
for analyses of HPV persistence and CIN2-3/HSILþ to main-
tain independence of observations. Sensitivity analyses sug-
gested that the results of this meta-analysis were robust to
reasonable changes in the decision rules, and funnel plot asym-
metry analyses showed little evidence of publication bias.
HPV persistence was strongly and consistently associated
with CIN2-3/HSILþ, emphasizing the value of HPV persis-
tence as a clinical marker and as an endpoint in clinical trials
and suggesting that sequential HPV DNA testing may be
useful for cervical cancer screening programs by identifying
women who are at high risk of cervical cancer.
The strength of the association between HPV persistence
and cervical neoplasia increased with increasing grade of
cervical disease. This trend supports the view that CIN1
represents active, mainly transient HPV infection and has
high rates of occurrence and regression among sexually
active women (76–79). In contrast, long-term HPV positiv-
ity is clearly associated with neoplastic transformation and
is thus clinically relevant to cervical cancer and its prevention.
The magnitude of effect for HPV persistence in predict-
ing CIN2-3/HSILþ varied widely and was partially depen-
dent on the HPV referent group. Comparing women with
persistent HPV infections with HPV-negative women
produced the highest relative risks because the risk of
CIN2-3/HSILþ approaches zero in HPV-negative women.
FIGURE 2. Relative risks (RRs) and 95% confidence intervals (CIs) for atypical squamous cells of undetermined significance (ASCUS); low-
grade cervical intraepithelial neoplasia (CIN1) and low-grade squamous intraepithelial lesions (LSIL); and high-grade cervical intraepithelial
neoplasia (CIN2-3), high-grade squamous intraepithelial lesions (HSILþ), and invasive cervical cancer in women with persistent human
papillomavirus infection compared with human papillomavirus-negative women in a meta-analysis of the published literature. Some RRs from the
same study were included in more than one disease category. Thus, 95% CIs for the ratios of RRs may be inaccurate, since observations were not
independent.
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Comparing women with persistent HPV infections to those
with transient infections potentially estimates the effect of
HPV persistence beyond exposure to short-term infection.
These comparisons produced the weakest relative risks,
which may suggest that the risk of CIN2-3/HSILþ is not
zero in women with HPV infections of short duration, as
previously shown (18, 80, 81), or that a proportion of women
with transient HPV infections actually had persistent infec-
tions prior to study initiation and were thus misclassified.
Associations between HPV persistence and cervical neo-
plasia also appeared stronger among studies with two re-
lated characteristics: longer duration of HPV infection (>12
months) and wider HPV testing intervals (>6 months or >12
months). These characteristics may represent a proxy for
longer exposure to the carcinogenic effect of HPVoncogene
activity, and thus greater likelihood of developing CIN2-3
and invasive cervical cancer. The observed increase in the
strength of the association for CIN2-3/HSILþ with increas-
ing HPV testing interval probably reflects decreased mis-
classification of both exposure and outcome, since most
HPV infections will clear and associated low-grade lesions
will regress during the testing interval.
Although the detection of HPV infection at two time
points has been criticized as being arbitrary (82), these data
clearly demonstrate that two HPV-positive visits are associ-
ated with increased risk of CIN2-3/HSILþ. This review
FIGURE 3. Relative risks (RRs) and 95% confidence intervals (CIs) for atypical squamous cells of undetermined significance (ASCUS); low-
grade cervical intraepithelial neoplasia (CIN1) and low-grade squamous intraepithelial lesions (LSIL); and high-grade cervical intraepithelial
neoplasia (CIN2-3), high-grade squamous intraepithelial lesions (HSILþ), and invasive cervical cancer in women with persistent human
papillomavirus infection compared with women with mixed human papillomavirus status in a meta-analysis of the published literature. Some RRs
from the same study were included in more than one disease category. Thus, 95% CIs for the ratios of RRs may be inaccurate, since observations
were not independent.
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confirms that repeated HPV detection does indicate an in-
creased risk of invasive cervical cancer and its precursors,
despite differences in HPV persistence definitions, HPV de-
tection techniques and testing intervals, cervical outcome
diagnoses, and other study characteristics.
Associations between HPV16 and/or HPV18 persistence
and CIN2-3/HSILþ were consistently positive in formal
analyses, albeit with notable heterogeneity (relative risks
ranged from 4.5 (95 percent CI: 0.24, 85.1) to 279.7 (95
percent CI: 16.0, 4,894.5)). However, few studies provided
sufficient data to obtain HPV16 and HPV18 type-specific
associations. Given that even a single detection of HPV16 or
HPV18 appears to strongly predict the development of CIN3
and cervical cancer (83, 84), future studies should focus on
associations with type-specific persistence.
Analyses of additional study characteristics were incon-
sistent across HPV referent groups, probably because of
random error from sparse data across strata that may have
masked true effects. Unreported but potentially important
explanatory factors (e.g., sensitivity, specificity, and
FIGURE 4. Relative risks (RRs) and 95% confidence intervals (CIs) for atypical squamous cells of undetermined significance (ASCUS); low-
grade cervical intraepithelial neoplasia (CIN1) and low-grade squamous intraepithelial lesions (LSIL); and high-grade cervical intraepithelial
neoplasia (CIN2-3), high-grade squamous intraepithelial lesions (HSILþ), and invasive cervical cancer in women with persistent human
papillomavirus infection compared with women with transient human papillomavirus infection in a meta-analysis of the published literature. Some
RRs from the same study were included in more than one disease category. Thus, 95% CIs for the ratios of RRs may be inaccurate, since
observations were not independent.
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reproducibility of HPV tests, cytology, colposcopy, and
histology) may also explain heterogeneity in associations
between HPV persistence and CIN2-3/HSILþ (85–91).
Although this review focused on the relative risk of CIN2-
3/HSILþ associated with HPV persistence, it is also impor-
tant to consider the absolute difference in risk of CIN2-3/
HSILþ for women with persistent HPV infection as com-
pared with women without persistent infection (92). To ap-
proximate absolute risk differences for the median relative
risks in figure 1, we estimated the baseline (unexposed) risk
of CIN2-3/HSILþ for the studies shown in figure 1. Because
the unexposed risk was zero in the cohort analyses, we used
the nested case-control studies when possible to roughly
estimate the median unexposed risks of CIN2-3/HSILþ
(16, 29–31, 37, 51), which were approximately 0.0005,
0.002, and 0.003 for the HPV-negative, mixed, and transient
referent groups, respectively. The mean or median duration
of follow-up, where stated, was approximately 2–8 years
(31, 37). Using these estimates, the median relative risks
in figure 1 correspond to risk differences of approximately
2 percent, 6 percent, and 4 percent, respectively (e.g., the risk
difference for the HPV-negative group was (33.5 3 0.0005)
 0.0005 ¼ 0.02). Thus, the ‘‘numbers needed to treat’’ (the
number of women required to have persistent HPV infection
to increase the number of incident CIN2-3/HSILþ cases by
1) are approximately 60, 15, and 24, respectively. For ex-
ample, persistent HPV infection results in a rough average
of approximately one extra CIN2-3/HSILþ case in every
60 women followed for about 5 years as compared with
HPV-negative women. These estimates, while very approx-
imate, provide some sense of the absolute difference in
risk.
Further research would benefit from standardized criteria
for the detection and reporting of HPV infections and cer-
vical neoplasia. Over one third of all relative risks used
a composite outcome of any cervical lesion/ASCUS as the
cervical outcome and thus could not be used to examine the
association of HPV persistence by specific grade of neopla-
sia. Testing intervals also varied widely. Several studies
have suggested that the median duration of HPV infection,
which may vary by HPV type, is approximately 1 year (10,
24, 57, 93–95). However, the testing interval was generally
6 months in these studies, which could have led to over-
estimation of median duration in those analyses. A recent
population-based study from Costa Rica suggests that more
than half of all HPV infections clear by 6 months (96). In
light of these data and the finding in this systematic review
that even testing intervals of 6 months produced strong
summary relative risks for the association between HPV
persistence and CIN2-3/HSILþ, repeat HPV DNA testing
at 6 months may be a valuable way to identify women at
increased risk of cervical precancer and cancer for clinical
purposes. Large studies of persistence and the natural his-
tory of precancer are emerging that will continue to inform
this issue (e.g., see Plummer et al. (97)).
Testing for persistent HPV DNA may be valuable for
cervical cancer screening, particularly given the higher sen-
sitivity of HPV DNA testing as compared with cytology for
CIN2-3þ (98, 99) and the underdetection of cervical neo-
plasia using colposcopy-directed biopsies (100, 101). A re-
liable definition of HPV persistence would have higher
specificity than a single cross-sectional measurement of
HPV and higher sensitivity than currently available cyto-
logic screening tests.
In conclusion, this systematic review showed that HPV
persistence is strongly associated with CIN2-3/HSILþ. The
magnitude of the effect of HPV persistence was stronger
with longer duration of infection, wider HPV testing inter-
vals, and higher-grade cervical disease. The overwhelm-
ingly positive associations identified in this review
validate the use of HPV persistence as a surrogate endpoint
in clinical trials and potentially in cervical cancer screening.
With standardization of definitions and testing, detection of
persistent HPV DNA can become a valuable marker of
CIN2-3 and cancer for clinical and research use.
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